Genomics Revolution Meets Regulatory Evolution: Why Personalized Medicine Is Taking So Long
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner Hamburg notes challenges of changing regulatory models to advance personalized medicine during AAAS/FDLI colloquium. But "we will establish a clear and illuminated pathway for product approval."
You may also be interested in...
"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon
The agency is planning a library of validated computer models of how patients respond to medical treatments.